{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T12:46:42Z","timestamp":1761396402667},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,11,10]],"date-time":"2022-11-10T00:00:00Z","timestamp":1668038400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,11,10]],"date-time":"2022-11-10T00:00:00Z","timestamp":1668038400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2023,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Triplet and doublet regimens of encorafenib plus cetuximab with and without binimetinib, respectively, were approved in Japan for unresectable, metastatic, <jats:italic>BRAF<\/jats:italic> V600E-mutated colorectal cancer (mCRC) that had progressed after 1\u20132 prior chemotherapies. This early post-marketing phase vigilance (EPPV) study collected adverse drug reactions (ADRs) from Japanese patients to ensure safety measures as appropriate.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Patients with <jats:italic>BRAF<\/jats:italic> V600E mCRC who received the triplet or doublet regimens in Japan were selected for this study. ADRs were collected as spontaneous reports between November 27, 2020 and May 26, 2021. Serious ADRs were evaluated according to guidelines of the International Council for Harmonisation and the EudraVigilance list of Important Medical Event Terms.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>An estimated 550 Japanese patients with mCRC received the triplet or doublet regimens during the 6-month EPPV period. Overall, 101 and 42 patients reported ADRs and serious ADRs, respectively. No ADRs leading to death were reported. The most frequently reported ADRs were nausea (17 patients), serous retinal detachment (16), decreased appetite (12), diarrhea (11), and vomiting (11). Among the important identified\/potential risks that are defined in the risk management plans for encorafenib and binimetinib, eye disorder-related ADRs were observed in 32 patients, rhabdomyolysis-related ADRs in 12, hemorrhage-related ADRs in 7, and hepatic dysfunction-related ADRs in 7. Of 22 patients with serious eye disorders, 20 recovered or were recovering during the EPPV period.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>The safety profile in this EPPV study was similar to that from the phase III BEACON CRC study and no new safety concerns were identified.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s10147-022-02264-z","type":"journal-article","created":{"date-parts":[[2022,11,10]],"date-time":"2022-11-10T15:04:31Z","timestamp":1668092671000},"page":"139-144","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Encorafenib, binimetinib, and cetuximab in BRAF V600E\u2013mutated colorectal cancer: an early post-marketing phase vigilance study"],"prefix":"10.1007","volume":"28","author":[{"given":"Hidenori","family":"Sakata","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maki","family":"Murase","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Kato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kensei","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenichi","family":"Sugihara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigenobu","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takayuki","family":"Yoshino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,11,10]]},"reference":[{"key":"2264_CR1","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1038\/bjc.2011.19","volume":"104","author":"T Yokota","year":"2011","unstructured":"Yokota T, Ura T, Shibata N et al (2011) BRAF mutation is a powerful prognostic factor in advanced and recurrent colorectal cancer. Br J Cancer 104:856\u2013862","journal-title":"Br J Cancer"},{"key":"2264_CR2","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1186\/s12885-015-1276-z","volume":"15","author":"A Kawazoe","year":"2015","unstructured":"Kawazoe A, Shitara K, Fukuoka S et al (2015) A retrospective observational study of clinicopathological features of KRAS, NRAS, BRAF, and PIK3CA mutations in Japanese patients with metastatic colorectal cancer. BMC Cancer 15:258","journal-title":"BMC Cancer"},{"key":"2264_CR3","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1002\/ijc.25555","volume":"128","author":"J Tie","year":"2011","unstructured":"Tie J, Gibbs P, Lipton L et al (2011) Optimizing targeted therapeutic development: analysis of a colorectal cancer patient population with the BRAFV600E mutation. Int J Cancer 128:2075\u20132084","journal-title":"Int J Cancer"},{"key":"2264_CR4","doi-asserted-by":"publisher","first-page":"4623","DOI":"10.1002\/cncr.26086","volume":"117","author":"B Tran","year":"2011","unstructured":"Tran B, Kopetz S, Tie J et al (2011) Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer. Cancer 117:4623\u20134632","journal-title":"Cancer"},{"key":"2264_CR5","doi-asserted-by":"publisher","first-page":"1632","DOI":"10.1056\/NEJMoa1908075","volume":"381","author":"S Kopetz","year":"2019","unstructured":"Kopetz S, Grothey A, Yaeger R et al (2019) Encorafenib, binimetinib, and cetuximab in BRAF V600E\u2013mutated colorectal cancer. N Engl J Med 381:1632\u20131643","journal-title":"N Engl J Med"},{"key":"2264_CR6","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/S1470-2045(18)30142-6","volume":"19","author":"R Dummer","year":"2018","unstructured":"Dummer R, Ascierto PA, Gogas HJ et al (2018) Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 19:603\u2013615","journal-title":"Lancet Oncol"},{"key":"2264_CR7","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1016\/S1470-2045(18)30497-2","volume":"19","author":"R Dummer","year":"2018","unstructured":"Dummer R, Ascierto PA, Gogas HJ et al (2018) Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 19:1315\u20131327","journal-title":"Lancet Oncol"},{"key":"2264_CR8","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.ejca.2019.11.016","volume":"126","author":"PA Ascierto","year":"2020","unstructured":"Ascierto PA, Dummer R, Gogas HJ et al (2020) Update on tolerability and overall survival in COLUMBUS: landmark analysis of a randomised randomized phase 3 trial of encorafenib plus binimetinib vs vemurafenib or encorafenib in patients with BRAF V600\u2013mutant melanoma. Eur J Cancer 126:33\u201344","journal-title":"Eur J Cancer"},{"key":"2264_CR9","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.ejca.2019.07.016","volume":"119","author":"HJ Gogas","year":"2019","unstructured":"Gogas HJ, Flaherty KT, Dummer R et al (2019) Adverse events associated with encorafenib plus binimetinib in the COLUMBUS study: incidence, course, and management. Eur J Cancer 119:97\u2013106","journal-title":"Eur J Cancer"},{"key":"2264_CR10","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1016\/j.ctrv.2013.01.003","volume":"39","author":"R Van der Noll","year":"2013","unstructured":"Van der Noll R, Leijen S, Neuteboom GHG et al (2013) Effect of inhibition of the FGFR-MAPK signaling pathway on the development of ocular toxicities. Cancer Treat Rev 39:664\u2013672","journal-title":"Cancer Treat Rev"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-022-02264-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-022-02264-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-022-02264-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,6]],"date-time":"2023-01-06T07:24:53Z","timestamp":1672989893000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10147-022-02264-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,10]]},"references-count":10,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["2264"],"URL":"https:\/\/doi.org\/10.1007\/s10147-022-02264-z","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,10]]},"assertion":[{"value":"21 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"HS is an employee and a stock holder of Ono. MM is an employee of Ono. TK received honoraria from Chugai, Eli Lilly, Ono, Taiho, Takeda, and Yakult Honsha, outside of the submitted work. KY received research funding from Eli Lilly Japan, Ono, Taiho, and Yakult Honsha; and honoraria from Bristol Myers Squibb, Daiichi Sankyo, Eli Lilly Japan, Ono, and Taiho, outside of the submitted work. KS received honoraria from Merck Serono, Ono, Taiho, and Yakult Honsha, outside of the submitted work. SS received honoraria from Ono, outside of the submitted work. TY received research funding from Amgen, Chugai, Daiichi Sankyo, Genomedia, MSD, Nippon Boehringer Ingelheim, Ono, Parexel International, Pfizer Japan, Sanofi, Sysmex, and Taiho; and honoraria from Bayer, Chugai, Eli Lilly Japan, Merck Biopharma, MSD, Ono, and Taiho, outside of the submitted work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}